Introduction

Oncology Letters

1792-1074 1792-1082

D.A. Spandidos

10.3892/ol.2019.10948

OL-0-0-10948

Review

The role of pyruvate kinase M2 in anticancer therapeutic treatments

Qiongli

1 Luo

Shengping

1 Tan

Qiuhong

1 Deng

Jun

2 Zhou

Sichun

2 Peng

Mei

3 Tao

Ting

4 Yang

Xiaoping

1Department of Pharmacy, Zhuzhou Central Hospital, Zhuzhou, Hunan 412000, P.R. China 2Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, School of Medicine, Hunan Normal University, Changsha, Hunan 410013, P.R. China 3Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China 4Department of Pharmacy, Yueyang Maternal-Child Medicine Health Hospital, Yueyang, Hunan 414000, P.R. China

Correspondence to: Ms. Qiongli Su, Department of Pharmacy, Zhuzhou Central Hospital, 116 Changjiang South Road, Tianyuan, Zhuzhou, Hunan 412000, P.R. China, E-mail: suqiongli151@163.com Dr Xiaoping Yang, Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, School of Medicine, Hunan Normal University, 371 Tongzipo Road, Changsha, Hunan 410013, P.R. China, E-mail: xiaoping.yang@hunnu.edu.cn

12 2019

02 10 2019

18 6 5663 5672 28012019 06092019

2019

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Cancer cells are characterized by a high glycolytic rate, which leads to energy regeneration and anabolic metabolism; a consequence of this is the abnormal expression of pyruvate kinase isoenzyme M2 (PKM2). Multiple studies have demonstrated that the expression levels of PKM2 are upregulated in numerous cancer types. Consequently, the mechanism of action of certain anticancer drugs is to downregulate PKM2 expression, indicating the significance of PKM2 in a chemotherapeutic setting. Furthermore, it has previously been highlighted that the downregulation of PKM2 expression, using either inhibitors or short interfering RNA, enhances the anticancer effect exerted by THP treatment on bladder cancer cells, both in vitro and in vivo. The present review summarizes the detailed mechanisms and therapeutic relevance of anticancer drugs that inhibit PKM2 expression. In addition, the relationship between PKM2 expression levels and drug resistance were explored. Finally, future directions, such as the targeting of PKM2 as a strategy to explore novel anticancer agents, were suggested. The current review explored and highlighted the important role of PKM2 in anticancer treatments.

PKM2 cancer chemotherapeutic drugs resistance target

1. Introduction

Cancer is a disease with a high prevalence and mortality rate, and its treatment represents a considerable clinical challenge. The benefits of current chemotherapeutics are limited due to their propensity to cause DNA damage in normal cells (1). Therefore, research has been directed towards finding safer and more sustainable cancer treatments. Notably, it has been demonstrated that targeting the regulation of tumor cell metabolism, without causing toxicity in normal cells, is a potential strategy for the treatment or adjuvant therapy of cancer (2).

The metabolic mechanism is one of a multitude of differential characteristics separating cancer cells from normal cells. Tumor cells are primarily dependent on aerobic glycolysis to obtain energy and produce lactate, even in the presence of oxygen (3). Recently, the targeting of cancer cell metabolism has gained traction as an effective strategy for the development of new cancer treatments (4,5). In 2017, the Food and Drug Administration approved Enasidenib (AG-221), an inhibitor of the mutant isocitrate dehydrogenase 2 (IDH2) protein, for the treatment of relapsed or refractory acute myeloid leukemia (6). In addition to IDH2, pyruvate kinase isoenzyme M2 (PKM2) has also emerged as a critical regulator of cancer cell metabolism. PK is an enzyme that plays a critical function in the glycolytic pathway, catalyzing the final, rate-limiting step of glycolysis by converting phosphoenolpyruvate and ADP to pyruvate and ATP, respectively (7,8). Alternate splicing of PKM pre-mRNA by heterogeneous nuclear ribonucleoprotein A1/2 and polypyrimidine-tract binding protein (PTBP1), results in PKM2 generation (9). There is mounting evidence that unlike other PK isoforms, PKM2 is upregulated in multiple carcinomas, including colorectal (10), lung (11), liver (12), breast cancer (13) and pancreatic ductal adenocarcinoma (14). The general molecular mechanisms involved in tumor growth are briefly summarized in Fig. 1.

The upregulation of PKM2 expression enhances chemosensitivity in breast (15), gastric (16) and colorectal cancer (17). High expression levels of PKM2 have been shown to be associated with increased chemosensitivity to 5-fluorouracil (5-FU) and epirubicin in breast and cervical cancer (15,18). By contrast, PKM2 contributes to gefitinib resistance via the upregulation of STAT3 in colorectal cancer (19). Moreover, the downregulation of PKM2 leads to cell apoptosis and increases the sensitivity of tumor cells to chemotherapy (20). This highlights the ability of PKM2 to alter cell sensitivity to chemotherapy.

The present review summarizes the advancements in targeting PKM2 expression as a novel therapeutic strategy. The underlying mechanisms, and the potential for future clinical translation, were also analyzed. An informative overview of PKM2 is detailed, establishing a precedent for the development of clinical therapeutics that target PKM2, for the treatment of cancer.

2. Biochemical role of PKM2 in physiological processes

PKM2 can function as: i) A metabolic enzyme; ii) a protein kinase; or iii) a transcriptional coactivator of genes that influence cell proliferation, migration and apoptosis. It has been demonstrated that the inhibition of PKM2 slows tumor growth or causes tumor cell death (21). Following PKM2 inhibition, a reduction in cancer cell proliferation and survival have both been observed (21,22). RNA interference and peptide aptamers that ablate PKM2 have been reported to elicit anticancer effects, such as the impairment of tumor growth, the induction of apoptotic cell death and increasing sensitivity to chemotherapy (20,23–26). Conversely, a PKM2 activator was proven to effectively induce apoptosis in lung cancer cells via the inhibition of AKT phosphorylation (27). The aforementioned findings support the hypothesis that PKM2 represents a promising therapeutic target.

Activators of PKM2 exert their effects by stabilizing the molecular in its tetramer form, subsequently affecting cancer cell metabolism and indicating a novel anti-cancer therapeutic strategy (28). To date, several PKM2 activators have been reported, including N,N′-diarylsulfonamide (29) and 2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones (30). The structures of certain PKM2 activators are detailed in Table I (29–35). Conversely, PKM2 inhibitors (such as shikonin; Fig. 2) have been studied and will be explored in the following sections.

3. PKM2-inhibitory compounds <sec> <title>Shikonin

Shikonin is an active chemical component extracted from Lithospermum erythrorhizon, which has been found to exert multiple pharmacological effects. Notably, it exhibits antitumor properties in numerous human cancer types (36,37). Shikonin has been identified as a PKM2 inhibitor and is able to reduce the rate of cancer cell glycolysis (38). Additionally, one study determined that shikonin improved the therapeutic efficacy of Taxol, and reduced chemoresistance to cisplatin in advanced bladder cancer (BC) via the inhibition of PKM2 (38). In summary, shikonin is able to inhibit tumor growth by suppressing aerobic glycolysis, which is mediated by PKM2 in vivo (39).

Li et al (40) demonstrated that PKM2 expression levels were higher in skin tumor tissues than normal tissues. Moreover, it was also observed that shikonin inhibited cancer-cell transformation and PKM2 activation, which was induced by the tumor promoter 12-O-tetradecanoylphorbol 13-acetate in the early stages of carcinogenesis. Furthermore, another study indicated that shikonin reduced epidermal growth factor receptor, PI3K, p-AKT, Hypoxia inducible factor-1α (HIF-1α) and PKM2 expression levels. Moreover, the viability of esophageal cancer cells was decreased and cell apoptosis was induced in the presence of shikonin (41). Additionally, increased expression levels of PKM2 increase the resistance of esophageal cancer cells to shikonin. It was observed that shikonin exerted its chemotherapeutic effects via the induction of cell apoptosis in vivo. To summarize, shikonin was determined to inhibit esophageal and bladder cancer progression via the inhibition of PKM2 expression (41,42).

However, because the clinical use of shikonin as an anticancer agent is still limited by its toxicity and poor solubility (43), it is problematic to incorporate directly into cancer therapy regimes. The study of PKM2 inhibitors is ongoing and the discovery of novel inhibitors with low toxicity would confer great benefit to patients with cancer (44).

Metformin

Metformin (a commonly prescribed drug used for the treatment of type II diabetes) has been extensively investigated as a metabolic modulator, but also exhibits anticancer properties. Epidemiological evidence has demonstrated that metformin exhibits high potential efficacy as an antitumor agent (45). Data gathered from multiple xenograft cancer models suggest that metformin may inhibit the progression and recrudescence of cancer (46).

Moreover, metformin induces tumor cell death and increases sensitivity to chemotherapeutic drugs via the inhibition of PKM2. For instance, Shang et al (47) demonstrated that metformin enhanced the sensitivity of osteosarcoma stem cells to cisplatin, by reducing the expression level of PKM2. Mechanistically, it was confirmed that upregulated expression levels of PKM2 were responsible for resistance to cisplatin in osteosarcoma stem cells. Additionally, PKM2 downregulation by metformin has been shown to result in the inhibition of glucose uptake, lactate production and ATP production in human osteosarcoma cancer stem cells (CSCs). Metformin was also found to exert a significant antitumor effect on gastric cancer cells via inhibition of the hypoxia-inducible factor (HIF)1α/PKM2 signaling pathway (48). Moreover, it was determined that the upregulation of PKM2 induced epithelial-mesenchymal transition (EMT), which in turn increased the invasion and metastatic potential of carcinoma cells (49). Cheng et al (50) discovered that metformin inhibits transforming growth factor β1 (TGF-β1)-induced EMT in cervical cancer cells, and also investigated the mechanisms involved in tumorigenesis (which reduced PKM2 expression levels). Furthermore, the present authors demonstrated that decreased PKM2 expression levels, induced by metformin, enhanced the efficiency of THP (Docetaxel, Trastuzumab and Pertuzumab) for BC treatment (51).

Vitamin K (VK)3 and 5

VK family members are essential and fat-soluble naphthoquinones that serve vital physiological roles (52). Numerous studies have suggested that VK3 and 5 are promising anticancer adjuvants, both in vitro and in vivo (53–57). It has been demonstrated that combination therapy with VK3 and vitamin C exerts a synergistic anticancer effect in Jurkat and K562 cells (58,59). VK3 also improves the efficacy of anticancer drugs such as doxorubicin (DOX) (58,60). Moreover, a clinical trial suggested that VK3 improves cell sensitivity to Inopera: Chen et al (61) discovered that VK3 and 5 inhibit PKM2 significantly more than PKM1 and pyruvate kinase isoenzyme L, while other isoforms of PK are predominantly expressed in most adult tissues and the liver. This study further demonstrated that VK3 and 5 have the potential to exert a therapeutic effect on cancer cells via the suppression of PKM2 expression.

Temozolomide (TMZ)

TMZ is an antitumor drug that damages DNA, and is used to treat glioblastoma (GBM). It also inhibits the rate of pyruvate-to-lactate transformation (62–64). Park et al (65) demonstrated that TMZ alters PKM2 expression, leading to changes in pyruvate metabolism, and highlighting that PKM2 plays a key role in the DNA-damage response.

4. PKM2 activity influences chemosensitivity

Resistance to chemotherapy is a major challenge concerning cancer treatment; therefore, overcoming the development of resistance in cancer cells remains a primary focus (66). Drug-resistant cancer cells exhibit an increased glycolytic rate, meaning that targeting glycolysis may represent a novel strategy to reduce the adverse effects of drug resistance (67). Therefore, the role of PKM2 in the development of chemoresistance in cancer cells, and the targeting of PKM2 expression, are important factors that could help to increase the sensitivity of cancer cells to chemotherapy.

<sec> <title>Gemcitabine (GEM)

GEM is a targeted drug metabolite with two fluorine atoms that has been suggested by the National Comprehensive Cancer Network guidelines as a first-line chemotherapeutic agent for the treatment of pancreatic cancer (68); however, only a small proportion of patients respond positively to GEM. Despite a meta-analysis showing that the combination of GEM with other therapeutics results in significantly higher disease response rates, and longer progression-free and overall survival, after several typical chemotherapy treatment cycles, the emergence of drug resistance often leads to therapeutic failure (69).

The resistance of pancreatic cancer cells to GEM involves PKM2 expression and its nonmetabolic function. Thus, PKM2 should be considered a therapeutic target in GEM-resistant pancreatic cancer cells (70,71). The role of PKM2 in GEM resistance is demonstrated in Fig. 3. Kim et al (72) discovered that PKM2-knockdown induced tumor protein 53 activation via the p38 mitogen-activated protein kinase signaling pathway, following treatment with GEM. Subsequent apoptosis was then induced through the activation of caspase 3/7 and poly ADP-ribose polymerase cleavage. These findings further indicate PKM2 as a novel target for the treatment of GEM resistance, and also support the combination of GEM with a PKM2 inhibitor for treating pancreatic cancer.

Calabretta et al (73) mechanistically characterized a novel PTBP1/PKM2 pro-survival pathway, triggered by chronic treatment of pancreatic ductal adenocarcinoma (PDAC) cells with GEM. It was observed that alternative splicing of PKM was found to be differently regulated in DR-PDAC cells, leading to an increase in the cancer-associated PKM2 isoform. Moreover, upregulation of PKM2 expression was also associated with shorter recurrence-free survival times in patients with PDAC. These findings indicate that PKM2 is a novel potential therapeutic target that may improve the response of PDAC to chemotherapy, and reduce the resistance of cancer cells to current treatments (73). Li et al (71) also determined that GEM resistance to pancreatic cancer cells is associated with a long intergenic non-protein coding RNA, regulator of reprogramming /PTBP1/PKM2 axis (71).

Platinum

Cisplatin, carboplatin and oxaliplatin (OXA) are typically used to treat human cancers. However, their clinical success is limited by severe side effects and intrinsic or acquired resistance (74).

Cisplatin

Cisplatin, the first discovered platinum anticancer drug, is active against a wide spectrum of solid neoplasms, including ovarian, bladder, colorectal and lung cancer (75–77). However, treatment with cisplatin often results in drug resistance and several adverse side effects (78).

Wang et al (76) determined that shikonin inhibited PKM2 and reduced BC cell survival time in a dose-dependent, but also a PK activity-independent manner. PKM2 upregulation is strongly associated with cisplatin resistance; however, cisplatin-resistant cells respond sensitively to shikonin when PKM2 is upregulated. In mice, the combination of shikonin and cisplatin significantly reduced BC growth and metastasis (in contrast to monotherapy with either drug). Thus, PKM2 is indicated as a key factor in the development of resistance to cisplatin treatment in advanced BC. Suppression of PKM2 via RNAi or specific inhibitors may be an effective approach to reducing resistance and improving the outcomes of patients with advanced BC (76). Furthermore, a study conducted by Shang et al (47) confirmed that osteosarcoma stem cells exhibit significantly higher levels of cisplatin resistance compared with osteosarcoma non-CSCs. The aforementioned results indicated that PKM2 upregulation caused resistance to cisplatin in osteosarcoma stem cells.

Zhu et al (18) collected tumor tissues from 36 patients with cervical cancer (pre- and post-chemotherapy). The expression levels of multiple tumor-associated proteins (including PKM2 and HIF1α) were then determined using immunohistochemistry. As a result, it was discovered that the mTOR/HIF-1α/c-Myc/PKM2 signaling pathway was significantly downregulated in patients with cervical cancer, following chemotherapy. It was then demonstrated that PKM2 inhibited the proliferation of cervical cancer cells, and enhanced their sensitivity to cisplatin in vitro. Additionally, PKM2 was inextricably associated with the mTOR pathway. PKM2 and mTOR expression in cervical cancer tissues may serve as predictive biomarkers for the use of cisplatin-based chemotherapy. Consequently, it was concluded that PKM2 increased the sensitivity of cervical cancer cells to cisplatin, by interacting with the mTOR signaling pathway.

It has been demonstrated that PKM2 is closely associated with the sensitivity of certain cancer cells to cisplatin. However, PKM2 may exert an opposing effect by either increasing or decreasing the antitumor activity of cisplatin. Table II summarizes the effect of PKM2 on the sensitivity of multiple tumors to cisplatin treatment (18,47,76,79,80).

Carboplatin

Carboplatin is also a platinum-based chemotherapeutic drug. It is an effective treatment for various solid tumor types, particularly non-small cell lung cancer (NSCLC) (81). However, NSCLC cells commonly develop resistance following carboplatin treatment (82). Liu et al (83) investigated carboplatin-resistant NSCLC models using the A549 and PC9 lung cancer cell lines, termed A549/R and PC9/R, respectively. It was discovered that as well as the low sensitivity of A549/R and PC9/R cells to carboplatin treatment, resistant cells exhibited higher glucose metabolism than wild type cells. Mechanistically, it was confirmed that a high expression level of PKM2 in A549/R and PC9/R cells was dependent on both a high rate of glucose metabolism, and carboplatin resistance (83).

OXA

OXA is a third-generation platinum-based compound (84) and is the first platinum-based therapy to categorically exhibit clinical activity against CRCs (85). However, an increasing number of research reports have detailed the development of OXA resistance in CRC therapy, and this has become problematic for its clinical application (86,87). Despite this, it has been elucidated that PKM2 is associated with OXA resistance in vitro (88,89). In conclusion, PKM2 may play an important role in the development of OXA resistance in cancer cells.

5-FU

5-FU is an anticancer drug, commonly used in the treatment of colon cancer. Acquired resistance is becoming a key challenge for the treatment of patients in the advanced stages of colon cancer (90). He et al (91) discovered that aerobic glycolysis was significantly upregulated in 5-FU-resistant cells (91). It was also reported that PKM2 is targeted by miR-122 in colon cancer cells. High expression levels of miR-122 in 5-FU-resistant cells has been shown to reduce resistance to 5-FU through the inhibition of PKM2, both in vitro and in vivo. In summary, research indicates that enhanced glucose metabolism reduces 5-FU resistance to cancer cells, and that the inhibition of glycolysis may be a possible therapeutic method to overcome 5-FU resistance (91,92).

DOX

DOX is an anticancer drug used to treat hepatocellular carcinoma. Acquired drug resistance following treatment represents a major challenge for both DOX and other chemotherapeutic agents. Pan et al (93) determined that the expression levels of miR-122 were lower in DOX-resistant Huh7/R cells compared with wild type cells, demonstrating that miR-122 is associated with chemoresistance to DOX. This was supported by the results of a luciferase reporter assay. High expression levels of miR-122 in Huh7/R cells were shown to reverse doxorubicin resistance via the inhibition of PKM2, leading to DOX-resistant cancer cell apoptosis. Therefore, it was demonstrated that the upregulation of glucose metabolism increases resistance to DOX, thus, inhibition of glycolysis by miR-122 may represent a potential therapeutic strategy to reduce DOX resistance in liver cancer (93).

Docetaxel

Docetaxel, a derivative of taxane, is an antineoplastic drug that is effective for the treatment of multiple malignant tumor types. It inhibits microtubule disassembly, consequently interfering with mitotic progress by blocking cells at the G₂/M checkpoint, and promoting apoptosis (94). Docetaxel is widely used to treat breast cancer (95–97), NSCLC (98,99) and other solid tumors (100), exhibiting significant therapeutic efficacy.

Shi et al (11) determined that combining plasmid short hairpin (sh)RNA-PKM2 with standard docetaxel treatment significantly improved its efficacy (11). Moreover, a significant reduction in the expression level of PKM2 markedly suppressed A549 cell proliferation (11). Yuan et al (66) investigated the effect of PKM2 silencing combined with docetaxel treatment, on cell viability, cell cycle distribution and apoptosis of the A549 and H460 NSCLC cell lines. shRNA-PKM2 could serve as a combination therapy with docetaxel in patients with NSCLC by reducing PKM2 expression, resulting in decreased cell viability, an increase in cell cycle arrest at the G₂/M checkpoint, and apoptosis. These results further suggest that targeting PKM2 has the potential to improve the treatment outcomes of patients with NSCLC, by increasing the chemotherapeutic efficacy of docetaxel (66).

5. Conclusions

Cancer is a fatal and prevalent disease with a high mortality rate worldwide, and it is predicted that the number of new cancer cases will increase to 19.3 million per year by 2025 (101). The reprogramming of cell metabolism is essential for tumorigenesis and is regulated by a complex network, in which PKM2 plays a critical role (102). PKM2 is typically upregulated in rapidly proliferating cells, such as cancerous and embryonic cells. It has been suggested that PKM2 plays an important role in cancer progression through the regulation of both metabolic and nonmetabolic pathways. Intermediate products of glycolysis, such as amino acids, nucleotides and lipids are required to sustain the rapid growth of cancer cells (103). Furthermore, high patient mRNA expression levels of PKM2 are associated with reduced median overall survival time (104). Interestingly, PKM2 can also serve as a biomarker, indicating patient sensitivity to chemotherapy. It has been demonstrated that downregulation of PKM2 expression improved the anticancer efficacy of THP treatment (51), thus, the clinical application of PKM2 activators and inhibitors in cancer therapy warrants further investigation.

In the present review, the antitumor effects of various PKM2 inhibitors were summarized. A multitude of in vitro and in vivo studies have determined the role of PKM2 in tumorigenesis and progression. Moreover, the effect of PKM2 on the sensitivity of cancer cells to certain clinically-available chemotherapeutic drugs was investigated. Numerous studies have confirmed that the inhibition of PKM2 increased tumor cell sensitivity to chemotherapy. However, PKM2 increased the sensitivity of cervical cancer cells to cisplatin by interacting with the mTOR pathway (18). The association between PKM2 expression and the development of resistance has been investigated in several types of cancer, albeit with conflicting results. A potential explanation for these discrepancies is that PKM2 has been proposed to fluctuate between different forms in order to regulate glucose metabolism. The low activity dimeric form supports cell growth by increasing the levels of glycolytic intermediates necessary for biosynthetic processes. However, when energy levels decrease, the enzyme can switch to the high activity tetrameric form and facilitate oxidative phosphorylation (20). Therefore, the resulting mechanisms may be quite different. Another explanation for the conflicting results may be that cancer cells possess the ability to alter their metabolism and regulate sensitivity to chemotherapeutics (80). Although PKM2 has become a focus of research in recent years, the development of specific inhibitors and activators of PKM2 remains to be achieved. Moreover, limited research has been conducted on results from clinical trials. It is suggested that the intervention of cancer cell metabolism via the precise regulation of PKM2 expression and activity may represent a promising translational application that warrants further investigation.

Acknowledgements

Not applicable.

Funding

The present review was supported by grants from the National Natural Science Foundation of China (grant no. 81874212), the Hunan Natural Science Foundation (grant no. 2016JJ2187), the Key Project of Hunan Province 2016 (grant no. 2016JC2036) and start-up funds of the Key Laboratory of Study and Discovery of Targeted Small Molecules of Hunan Province (grant no. 2017TP020) to XY, and from the National Natural Science Foundation of China (grant no. 81703008) and the Institutional Fund of Xiangya Hospital Central South University (grant no. 2016Q02) to MP.

Availability of data and materials

Not applicable.

Authors' contributions

QS wrote the manuscript draft. QS, QT, JD, SZ, MP and TT contributed to the preparation of the manuscript. XY and SL revised the manuscript. QS, DJ and XY conceived the design of the figures. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Abbreviations

PKM2

pyruvate kinase isoenzyme M2

PTBP1

polypyrimidine tract-binding protein 1

HIF-1α

hypoxia inducible factor 1 alpha

CSCs

cancer stem cells

EMT

epithelial-mesenchymal transition

TGF-β1

transforming growth factor β1

P53

tumor protein 53

mTOR

mammalian target of rapamycin

overall survival

PDAC

pancreatic ductal adenocarcinoma

CRC

colorectal cancer

NSCLC

non-small-cell lung carcinoma

References 1

Wang

Zhou

Chen

Zhang

Deng

Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells

Clin Epigenetics9832017

10.1186/s13148-017-0377-8

28814980

Ward

Thompson

Metabolic reprogramming: A cancer hallmark even warburg did not anticipate

Cancer Cell212973082012

10.1016/j.ccr.2012.02.014

22439925

Vander Heiden

Cantley

Thompson

Understanding the Warburg effect: The metabolic requirements of cell proliferation

Science324102910332009

10.1126/science.1160809

19460998

Kang

Ward

DeNicola

Recent advances in cancer metabolism: A technological perspective

Exp Mol Med50312018

10.1038/s12276-018-0027-z

29657324

Martinez-Outschoorn

Peiris-Pagés

Pestell

Sotgia

Lisanti

Cancer metabolism: A therapeutic perspective

Nat Rev Clin Oncol1411312017

10.1038/nrclinonc.2016.60

27141887

Stein

DiNardo

Pollyea

Fathi

Roboz

Altman

Stone

DeAngelo

Levine

Flinn

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Blood1307227312017

10.1182/blood-2017-04-779405

28588020

Bayley

Devilee

The Warburg effect in 2012

Curr Opin Oncol2462672012

10.1097/CCO.0b013e32834deb9e

22123234

Mazurek

Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells

Int J Biochem Cell Biol439699802011

10.1016/j.biocel.2010.02.005

20156581

Shinohara

Taniguchi

Kumazaki

Yamada

Ito

Otsuki

Uno

Hayakawa

Minami

Naoe

Akao

Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia

Cancer Lett36028382015

10.1016/j.canlet.2015.01.039

25644089

Taniguchi

Sugito

Kumazaki

Shinohara

Yamada

Nakagawa

Ito

Otsuki

Uno

Uchiyama

Akao

MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback cascade in colorectal cancer

Cancer Lett36317272015

10.1016/j.canlet.2015.03.026

25818238

Shi

Zhang

Wang

Yang

Zhang

Wang

Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice

Cancer Sci101144714532010

10.1111/j.1349-7006.2010.01562.x

20507318

Zheng

Lin

Meng

Wang

Yang

Xin

Long noncoding RNA MEG3 suppresses liver cancer cells growth through inhibiting β-catenin by activating PKM2 and inactivating PTEN

Cell Death Dis92532018

10.1038/s41419-018-0305-7

29449541

Benesch

Schneider

Voelker

Kapp

Caffier

Krockenberger

Dietl

Kammerer

Schmidt

The clinicopathological and prognostic relevance of pyruvate kinase M2 and pAkt expression in breast cancer

Anticancer Res30168916942010

20592362

Lockney

Zhang

Sopha

Washington

Merchant

Zhao

Shyr

Chakravarthy

Xia

Pyruvate kinase muscle isoenzyme 2 (PKM2) expression is associated with overall survival in pancreatic ductal adenocarcinoma

J Gastrointest Cancer463903982015

10.1007/s12029-015-9764-6

26385349

Lin

Liu

Guo

Fan

High expression of pyruvate kinase M2 is associated with chemosensitivity to epirubicin and 5-fluorouracil in breast cancer

J Cancer6113011392015

10.7150/jca.12719

26516361

Yoo

Hong

Shin

Park

Kim

Park

Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines

Int J Cancer1085325392004

10.1002/ijc.11604

14696117

Martinez-Balibrea

Plasencia

Ginés

Martinez-Cardús

Musulén

Aguilera

Manzano

Neamati

Abad

A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines

Mol Cancer Ther87717782009

10.1158/1535-7163.MCT-08-0882

19372549

Zhu

Zhang

Luo

Shen

Cheng

Zhu

PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer

Sci Rep6307882016

10.1038/srep30788

27492148

Zhang

Chen

Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer

Sci Rep5160822015

10.1038/srep16082

26542452

Christofk

Vander Heiden

Harris

Ramanathan

Gerszten

Wei

Fleming

Schreiber

Cantley

The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth

Nature4522302332008

10.1038/nature06734

18337823

Prakasam

Singh

Iqbal

Saini

Tiku

Bamezai

RNK

Pyruvate kinase M knockdown-induced signaling via AMP-activated protein kinase promotes mitochondrial biogenesis, autophagy, and cancer cell survival

J Biol Chem29215561155762017

10.1074/jbc.M117.791343

28778925

Zheng

Liu

Zeng

Geng

Ouyang

Wang

Huang

Overexpression of pyruvate kinase type M2 (PKM2) promotes ovarian cancer cell growth and survival via regulation of cell cycle progression related with upregulated CCND1 and downregulated CDKN1A expression

Med Sci Monit24310331122018

10.12659/MSM.907490

29752805

Goldberg

Sharp

Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression

J Exp Med2092172242012

10.1084/jem.20111487

22271574

Spoden

Mazurek

Morandell

Bacher

Ausserlechner

Jansen-Dürr

Eigenbrodt

Zwerschke

Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation

Int J Cancer1233123212008

10.1002/ijc.23512

18425820

Spoden

Rostek

Lechner

Mitterberger

Mazurek

Zwerschke

Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply

Exp Cell Res315276527742009

10.1016/j.yexcr.2009.06.024

19563799

Guo

Zhang

Chen

Wang

Xue

Zhang

Xiao

Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model

J Cancer Res Clin Oncol13765722011

10.1007/s00432-010-0860-5

20336315

Fan

Shi

Zhu

Wang

Luo

Pan

Yao

Leung

Liu

Identification of a new pyruvate kinase M2 isoform (PKM2) activator for the treatment of non-small-cell lung cancer (NSCLC)

Chem Biol Drug Des92185118582018

10.1111/cbdd.13354

29931766

Liu

Yuan

Zhang

Wang

Synthesis of novel 7-azaindole derivatives containing pyridin-3-ylmethyl dithiocarbamate moiety as potent PKM2 activators and PKM2 nucleus translocation inhibitors

Eur J Med Chem1701152019

10.1016/j.ejmech.2019.03.003

30878825

Boxer

Jiang

Vander Heiden

Shen

Skoumbourdis

Southall

Veith

Leister

Austin

Park

Evaluation of substituted N,N′-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase

J Med Chem53104810552010

10.1021/jm901577g

20017496

Guo

Linton

Jalaie

Kephart

Ornelas

Pairish

Greasley

Richardson

Maegley

Hickey

Discovery of 2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones as novel PKM2 activators

Bioorg Med Chem Lett23335833632013

10.1016/j.bmcl.2013.03.090

23622982

Guo

Long

Ding

Yan

Natural product micheliolide (MCL) irreversibly activates pyruvate kinase M2 and suppresses leukemia

J Med Chem61415541642018

10.1021/acs.jmedchem.8b00241

29641204

Jiang

Boxer

Vander Heiden

Shen

Skoumbourdis

Southall

Veith

Leister

Austin

Park

Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase

Bioorg Med Chem Lett20338733932010

10.1016/j.bmcl.2010.04.015

20451379

Matsui

Yasumatsu

Asahi

Kitamura

Kanai

Ubukata

Hayasaka

Takaishi

Hanzawa

Katakura

Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator

Bioorg Med Chem25354035462017

10.1016/j.bmc.2017.05.004

28511909

Keenan

Ishikado

Kannt

Sadowski

Yorek

Lockhart

Coppey

Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction

Nat Med237537622017

10.1038/nm.4328

28436957

Yacovan

Ozeri

Kehat

Mirilashvili

Sherman

Aizikovich

Shitrit

Ben-Zeev

Schutz

Bohana-Kashtan

1-(sulfonyl)-5-(arylsulfonyl)indoline as activators of the tumor cell specific M2 isoform of pyruvate kinase

Bioorg Med Chem Lett22646064682012

10.1016/j.bmcl.2012.08.054

22963766

Chen

Xiao

Huang

Yang

Wan

Shikonin induces apoptosis and necroptosis in pancreatic cancer via regulating the expression of RIP1/RIP3 and synergizes the activity of gemcitabine

Am J Transl Res9550755172017

29312502

Lin

Chang

Mitapalli

Hsiao

Yin

Yang

Shikonin-enhanced cell immunogenicity of tumor vaccine is mediated by the differential effects of DAMP components

Mol Cancer141742015

10.1186/s12943-015-0435-9

26403780

Chen

Xie

Jiang

Wang

Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2

Oncogene30429743062011

10.1038/onc.2011.137

21516121

Zhao

Zhu

Jiang

Jia

Zen

Shikonin inhibits tumor growth in mice by suppressing pyruvate kinase M2-mediated aerobic glycolysis

Sci Rep8145172018

10.1038/s41598-018-31615-y

30266938

Liu

Zhao

PKM2 inhibitor shikonin suppresses TPA-induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells

Mol Carcinog534034122014

10.1002/mc.21988

23255458

Tang

Zhao

Long

Chen

Jiang

Ren

Yang

Efficacy of Shikonin against esophageal cancer cells and its possible mechanisms in vitro and in vivo

J Cancer932402018

10.7150/jca.21224

29290767

Tao

Deng

Zhou

Zhuang

Huang

Peng

Downr-egulation of PKM2 decreases FASN expression in bladder cancer cells through AKT/mTOR/SREBP-1c axis

J Cell Physiol234308831042019

10.1002/jcp.27129

30221356

Boulos

Rahama

Hegazy

Efferth

Shikonin derivatives for cancer prevention and therapy

Cancer Lett4592482672019

10.1016/j.canlet.2019.04.033

31132429

Ning

Jin

McNutt

Yin

Synthesis and antitumor activity of novel 2, 3-didithiocarbamate substituted naphthoquinones as inhibitors of pyruvate kinase M2 isoform

J Enzyme Inhib Med Chem331261292018

10.1080/14756366.2017.1404591

29185365

Ruiter

Visser

van Herk-Sukel

Coebergh

Haak

Geelhoed-Duijvestijn

Straus

Herings

Stricker

Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: Results from a large population-based follow-up study

Diabetes Care351191242012

10.2337/dc11-0857

22100960

Dalva-Aydemir

Bajpai

Martinez

Adekola

Kandela

Wei

Singhal

Koblinski

Raje

Rosen

Shanmugam

Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin

Clin Cancer Res21116111712015

10.1158/1078-0432.CCR-14-1088

25542900

Shang

Guo

Liu

Metformin increases sensitivity of osteosarcoma stem cells to cisplatin by inhibiting expression of PKM2

Int J Oncol50184818562017

10.3892/ijo.2017.3950

28393220

Silvestri

Palumbo

Rasi

Posca

Pavlidou

Paoluzi

Castagnoli

Cesareni

Metformin induces apoptosis and downregulates pyruvate kinase M2 in breast cancer cells only when grown in nutrient-poor conditions

PLoS One10e01362502015

10.1371/journal.pone.0136250

26291325

Hamabe

Konno

Tanuma

Shima

Tsunekuni

Kawamoto

Nishida

Koseki

Mimori

Gotoh

Role of pyruvate kinase M2 in transcriptional regulation leading to epithelial-mesenchymal transition

Proc Natl Acad Sci USA11115526155312014

10.1073/pnas.1407717111

25313085

Cheng

Hao

Metformin inhibits TGF-β1-induced Epithelial-to-Mesenchymal transition via PKM2 relative-mTOR/p70s6k signaling pathway in cervical carcinoma cells

Int J Mol Sci17piiE20002016

10.3390/ijms17122000

27916907

Tao

Tang

Deng

Darko

Zhou

Peng

Zeng

Chen

Yang

Down-regulation of PKM2 enhances anticancer efficiency of THP on bladder cancer

J Cell Mol Med22277427902018

10.1111/jcmm.13571

29512924

Hey

Vitamin K-what, why, and when

Arch Dis Child Fetal Neonatal Ed88F80F832003

10.1136/fn.88.2.F80

12598491

Ogawa

Nakai

Deguchi

Nonomura

Masaki

Uchida

Yoshiji

Kuriyama

Vitamins K2, K3 and K5 exert antitumor effects on established colorectal cancer in mice by inducing apoptotic death of tumor cells

Int J Oncol313233312007

17611688

Ivanova

Zhelev

Getsov

Nikolova

Aoki

Higashi

Bakalova

Vitamin K: Redox-modulation, prevention of mitochondrial dysfunction and anticancer effect

Redox Biol163523582018

10.1016/j.redox.2018.03.013

29597144

Hitomi

Nonomura

Yokoyama

Yoshiji

Ogawa

Nakai

Deguchi

Masaki

Inoue

Kimura

In vitro and in vivo antitumor effects of vitamin K5 on hepatocellular carcinoma

Int J Oncol26133713442005

15809726

Yamada

Osada

Tanahashi

Matsui

Sasaki

Tanaka

Okumura

Matsuhashi

Takahashi

Yamaguchi

Yoshida

Novel therapy for locally advanced triple-negative breast cancer

Int J Oncol47126612722015

10.3892/ijo.2015.3113

26252842

Osada

Saji

Osada

Critical role of extracellular signal-regulated kinase phosphorylation on menadione (vitamin K3) induced growth inhibition

Cancer91115611652001

10.1002/1097-0142(20010315)91:6<1156::AID-CNCR1112>3.0.CO;2-1

11267961

Lamson

Plaza

The anticancer effects of vitamin K

Altern Med Rev83033182003

12946240

Bonilla-Porras

Jimenez-Del-Rio

Velez-Pardo

Vitamin K3 and vitamin C alone or in combination induced apoptosis in leukemia cells by a similar oxidative stress signalling mechanism

Cancer Cell Int11192011

10.1186/1475-2867-11-19

21663679

Parekh

Mansuri-Torshizi

Srivastava

Chitnis

Circumvention of adriamycin resistance: Effect of 2-methyl-1,4-naphthoquinone (vitamin K3) on drug cytotoxicity in sensitive and MDR P388 leukemia cells

Cancer Lett611471561992

10.1016/0304-3835(92)90173-S

1730138

Chen

Jiang

Wang

Vitamin K(3) and K(5) are inhibitors of tumor pyruvate kinase M2

Cancer Lett3162042102012

10.1016/j.canlet.2011.10.039

22154083

Scicchitano

Sorrentino

Proietti

Lama

Dobrowolny

Catizone

Binda

Larocca

Sica

Levetiracetam enhances the temozolomide effect on glioblastoma stem cell proliferation and apoptosis

Cancer Cell Int181362018

10.1186/s12935-018-0626-8

30214378

Johnson

O'Neill

Glioblastoma survival in the United States before and during the temozolomide era

J Neurooncol1073593642012

10.1007/s11060-011-0749-4

22045118

Chu

Wang

Yan

Song

Zhao

Sun

Liu

Zhang

Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting

Drug Deliv25163416412018

10.1080/10717544.2018.1494226

30176744

Park

Mukherjee

Ito

Chaumeil

Jalbert

Gaensler

Ronen

Nelson

Pieper

Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells

Cancer Res74711571242014

10.1158/0008-5472.CAN-14-0849

25320009

Yuan

Qiao

Zhuang

Chen

Xing

Zhang

Knockdown of the M2 isoform of pyruvate kinase (PKM2) with shRNA enhances the effect of docetaxel in human NSCLC cell lines in vitro

Yonsei Med J57131213232016

10.3349/ymj.2016.57.6.1312

27593857

Cheng

Xie

Wang

Qin

Zhang

PTBP1 knockdown overcomes the resistance to vincristine and oxaliplatin in drug-resistant colon cancer cells through regulation of glycolysis

Biomed Pharmacother1081942002018

10.1016/j.biopha.2018.09.031

30219676

Taieb

Pointet

Van Laethem

Laquente

Pernot

Lordick

Reni

What treatment in 2017 for inoperable pancreatic cancers?

Ann Oncol28147314832017

10.1093/annonc/mdx174

28459988

Sun

Ansari

Andersson

Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?

World J Gastroenterol18494449582012

10.3748/wjg.v18.i35.4944

23002368

Tian

Sheng

Jin

Upregulation of pyruvate kinase M2 expression by fatty acid synthase contributes to gemcitabine resistance in pancreatic cancer

Oncol Lett15221122172018

29434927

Zhao

Zhou

Liu

Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis

Cancer Chemother Pharmacol78119912072016

10.1007/s00280-016-3178-4

27785603

Kim

Park

Kang

You

Jung

Koo

Kim

Hong

Lee

Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells

Exp Cell Res3361191292015

10.1016/j.yexcr.2015.05.017

26112218

Calabretta

Bielli

Passacantilli

Pilozzi

Fendrich

Capurso

Fave

Sette

Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells

Oncogene35203120392016

10.1038/onc.2015.270

26234680

Dilruba

Kalayda

Platinum-based drugs: Past, present and future

Cancer Chemother Pharmacol77110311242016

10.1007/s00280-016-2976-z

26886018

Belanger

Fortier

Dubé

Lemay

Buisson

Masson

Elsherbiny

Costantino

Carmona

Mes-Masson

Replication protein A availability during DNA replication stress is a major determinant of cisplatin resistance in ovarian cancer cells

Cancer Res78556155732018

10.1158/0008-5472.CAN-18-0618

30072396

Wang

Zhang

Inhibition of pyruvate kinase M2 markedly reduces chemoresistance of advanced bladder cancer to cisplatin

Sci Rep7459832017

10.1038/srep45983

28378811

Galanski

Recent developments in the field of anticancer platinum complexes

Recent Pat Anticancer Drug Discov12852952006

10.2174/157489206777442287

18221042

Galluzzi

Senovilla

Vitale

Michels

Martins

Kepp

Castedo

Kroemer

Molecular mechanisms of cisplatin resistance

Oncogene31186918832012

10.1038/onc.2011.384

21892204

Wang

Hao

Nan

Jia

Chen

PKM2 inhibitor shikonin overcomes the cisplatin resistance in bladder cancer by inducing necroptosis

Int J Biol Sci14188318912018

10.7150/ijbs.27854

30443191

Qiu

Hao

Zhao

Deng

Shu

Dauricine upregulates the chemosensitivity of hepatocellular carcinoma cells: Role of repressing glycolysis via miR-199a: HK2/PKM2 modulation

Food Chem Toxicol1211561652018

10.1016/j.fct.2018.08.030

30171973

Miya

Kobayashi

Hino

Ando

Takeuchi

Seike

Kubota

Gemma

East Japan Chesters Group

Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy

Springerplus520802016

10.1186/s40064-016-3769-x

28018788

Sève

Dumontet

Chemoresistance in non-small cell lung cancer

Curr Med Chem Anticancer Agents573882005

10.2174/1568011053352604

15720263

Liu

Huang

Metformin partially reverses the carboplatin-resistance in NSCLC by inhibiting glucose metabolism

Oncotarget875206752162017

29088858

Kelland

The resurgence of platinum-based cancer chemotherapy

Nat Rev Cancer75735842007

10.1038/nrc2167

17625587

Graham

Mushin

Kirkpatrick

Oxaliplatin

Nat Rev Drug Discov311122004

10.1038/nrd1287

14756144

Hsu

Chen

Baskaran

Lin

Day

Lin

Vijaya Padma

Kuo

Huang

Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis

J Cell Physiol233545854672018

10.1002/jcp.26406

29247488

Fang

Gong

Zhou

Hassan

Wang

Chen

NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling

Cancer Lett41558722018

10.1016/j.canlet.2017.11.040

29203250

Lin

Fan

Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells

Oncotarget844171441852017

28498807

Ginés

Bystrup

Ruiz de Porras

Guardia

Musulén

Martínez-Cardús

Manzano

Layos

Abad

Martínez-Balibrea

PKM2 subcellular localization is involved in oxaliplatin resistance acquisition in HT29 human colorectal cancer cell lines

PLoS One10e01238302015

10.1371/journal.pone.0123830

25955657

Russo

Maiolino

Pagliara

Ungaro

Tatangelo

Leone

Scalia

Budillon

Quaglia

Russo

Enhancement of 5-FU sensitivity by the proapoptotic rpL3 gene in p53 null colon cancer cells through combined polymer nanoparticles

Oncotarget779670796872016

10.18632/oncotarget.13216

27835895

Xie

Tong

Peng

Huang

Wang

Liang

Overexpression of microRNA-122 re-sensitizes 5-FU-resistant colon cancer cells to 5-FU through the inhibition of PKM2 in vitro and in vivo

Cell Biochem Biophys70134313502014

10.1007/s12013-014-0062-x

24898807

Hjerpe

Egyhazi Brage

Carlson

Frostvik Stolt

Schedvins

Johansson

Shoshan

Avall-Lundqvist

Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer

BMC Clin Pathol13302013

10.1186/1472-6890-13-30

24252137

Pan

Wang

Shi

Zheng

Chen

Jin

Pan

MiR-122 reverses the doxorubicin-resistance in hepatocellular carcinoma cells through regulating the tumor metabolism

PLoS One11e01520902016

10.1371/journal.pone.0152090

27138141

Han

Shang

Tian

Docetaxel enhances apoptosis and G2/M cell cycle arrest by suppressing mitogen-activated protein kinase signaling in human renal clear cell carcinoma

Genet Mol Res152016doi: 10.4238/gmr.15017321

Sim

Bergh

Hellström

Hatschek

Xie

Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patients

Pharmacogenomics19125912682018

10.2217/pgs-2018-0080

30196760

van Rossum

AGJ

Kok

van Werkhoven

Opdam

Mandjes

IAM

van Leeuwen-Stok

van Tinteren

Imholz

ALT

Portielje

JEA

Bos

MMEM

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)

Eur J Cancer10240482018

10.1016/j.ejca.2018.07.013

30125761

Sharma

López-Tarruella

García-Saenz

Khan

Gómez

Prat

Moreno

Jerez-Gilarranz

Barnadas

Picornell

Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel

Clin Cancer Res24582058292018

10.1158/1078-0432.CCR-18-0585

30061361

Hata

Katakami

Shimokawa

Mitsudomi

Yamamoto

Nakagawa

Docetaxel Plus RAmucirumab with primary prophylactic pegylated Granulocyte-ColONy stimulating factor support for elderly patients with advanced Non-small-cell lung cancer: A multicenter prospective single arm phase II Trial: DRAGON study (WJOG9416L)

Clin Lung Cancer19e865e8692018

10.1016/j.cllc.2018.07.009

30206044

Tanimura

Uchino

Tamiya

Kaneko

Yamada

Yoshimura

Takayama

Treatment rationale and design of the RAMNITA study: A phase II study of the efficacy of docetaxel + ramucirumab for non-small cell lung cancer with brain metastasis

Medicine (Baltimore)97e110842018

10.1097/MD.0000000000011084

29879079

100

Milbar

Kates

Chappidi

Pederzoli

Yoshida

Sankin

Pierorazio

Schoenberg

Bivalacqua

Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with Non-muscle invasive bladder cancer

Bladder Cancer32933032017

10.3233/BLC-170126

29152553

101

Mortimer

Zonder

Pal

Lessons learned from the bevacizumab experience

Cancer Control193093162012

10.1177/107327481201900407

23037498

102

Wong

Ojo

Yan

Tang

PKM2 contributes to cancer metabolism

Cancer Lett3561841912015

10.1016/j.canlet.2014.01.031

24508027

103

Hsu

Hung

Pyruvate kinase M2 fuels multiple aspects of cancer cells: From cellular metabolism, transcriptional regulation to extracellular signaling

Mol Cancer17352018

10.1186/s12943-018-0791-3

29455645

104

Papadaki

Sfakianaki

Lagoudaki

Giagkas

Ioannidis

Trypaki

Tsakalaki

Voutsina

Koutsopoulos

Mavroudis

PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer

Br J Cancer111175717642014

10.1038/bjc.2014.492

25233397

Figure 1.

Pathways related to tumor growth involving PKM2. PKM2 is phosphorylated by ERK2 or PI3K/AKT resulting the nuclear translocation of PKM2. Nuclear PKM2 binds to proteins upregulating transcriptional activity, thereby promoting the Warburg effect and tumorigenesis; hnRNP induces PKM2 via alternative splicing of PKM genes to stimulate cancer cell invasion and migration. PKM2, pyruvate kinase isoenzyme M2; HIF1α, hypoxia inducible factor 1α; hnRNP, heterogeneous nuclear ribonucleoproteins; MLC2, myosin light chain 2; PARP, poly(ADP-ribose) polymerase 1; BUB3, BUB3 mitotic checkpoint protein; OCT4, octamer-binding transcription factor 4.

Figure 2.

Chemical structure of shikonin.

Figure 3.

Major role of PKM2 in gemcitabine resistance. The lincROR/miR-124/PTBP1/PKM2 complex is involved in the regulation of gemcitabine resistance. FASN regulates PKM2 expression and is associated with gemcitabine resistance. LincROR, long intergenic non-protein coding RNA, regulator of reprogramming PKM2, pyruvate kinase isoenzyme M2; PTBP1, polypyrimidine tract binding protein; FASN, Fatty acid synthase; miR, micro RNA.

Table I.

Structures of representative PKM2 activators.

PKM2 activators	Structures	(Refs.)
Micheliolide		(31)
Diarylsulfonamides		(29)
Thieno[3,2-b]pyrrole[3,2-d]pyridazinones		(32)
4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide		(33)
TEPP-46		(34)
2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones		(30)
1-(sulfonyl)-5-(arylsulfonyl)indoline		(35)

PKM2, pyruvate kinase isoenzyme M2.

Table II.

Effect of pyruvate kinase isoenzyme M2 on cisplatin sensitivity in different cancers.

Cancer type	Effect	Treatment	(Refs.)
Bladder cancer	Overcomes resistance	Shikonin	(76,79)
Hepatocellular carcinoma	Chemosensitivity	MicroRNA-199a	(80)
Osteosarcoma	Chemosensitivity	Metformin	(47)
Cervical cancer	Chemosensitivity	PKM2	(18)

PKM2, pyruvate kinase isoenzyme M2.